Uncontrolled use of vitamin B12 could potentially obscure the accurate diagnosis of pernicious anemia
AHK-Cu is a synthetic analog of GHK-Cu (glycyl-L-histidyl-L-lysine-copper), modified at the histidine position to increase tissue retention and reduce enzymatic degradation
Individuals diagnosed with pernicious anemia, a condition where the body cannot absorb B12 from the digestive tract, are prime candidates for these injections
Due to the compounds plasma half-life of approximately 3.86.9 hours [4] , twice-daily (BID) dosing may provide more sustained NNMT inhibition
Additionally, individuals experiencing certain neurological symptoms or those with high levels of homocysteine, a risk factor for cardiovascular diseases, might find our B12 injections beneficial
The compound cannot be misbranded, mislabeled or misused for non-research purposes under any circumstances